FLGT
Fulgent Genetics, Inc.
Diagnostics & Research · Healthcare · United States
20.62
close · 2026-10-30
value
55
cheaper than peers55
quality
28
stronger fundamentals28
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | 41.4% | 98 |
| earnings yield, 3 years ago | 22.5% | 98 |
| price to book | 0.57× | 98 |
| price to sales | 1.75× | 89 |
| cash flow yield, 2 years ago | 0.8% | 63 |
| earnings yield, 1 year ago | -6.8% | 21 |
| cash flow yield, 1 year ago | -3.4% | 18 |
| earnings yield, latest year | -9.6% | 18 |
| earnings yield, 2 years ago | -27.3% | 11 |
| cash flow yield, latest year | -21.9% | 8 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.0% | 98 |
| return on equity | -8.1% | 33 |
| revenue growth | 4.4% | 21 |
| operating margin | -39.4% | 5 |
4 of 4 measures available
Facts
| market cap | $567M |
| free cash flow | -$90.9M |
| employees | 1,315 |
| first trade | 2016-09-29 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.97 | -1.41 | -5.63 | 4.63 |
| free cash flow | -$124.2M | -$19.3M | $4.8M | $234.7M |
| net income | -$60.5M | -$42.7M | -$167.8M | $143.4M |
| revenue | $322.7M | $283.5M | $289.2M | $619.0M |
| unusual items | -$9.9M | -$10.1M | -$120.2M | -$3.0M |